Amarin Corp Plc (AMRN)

[ziploc_1]

KM was remarkably open in his recent talk at the H.C. Wainright conference...QUOTE

"So fixed dose combination is a very significant initiative. It is supporting the diversification element on our side. When you get a product like VASCEPA with 25% or 30% outcome benefit, it would be a shame not to imagine a full portfolio of products around it....Now because of the cost reduction, and we are very, very cash prudent today, we decided to focus on 1 statin in terms of development and really go sequential in terms of planning....meaning NOT TAKE RISKS to run different phases in parallel."

It is clear that deficient cash is the main factor holding up Amarin's development of a fixed dose combo of Vascepa with a statin or MD-2119 with a statin.

Amarin can not raise cash by selling their low priced stock or by borrowing at high interest rates...one solution is to sell to a BP flushed with cash....IMO pure EPA would have a much greater greater future in the hands of a BP than in the hands of a small cash poor Pharma.